Longeveron: other events

Form 8-K filed Oct 26, 2026 · items 8.01

FDA decisionsLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating

What the filing says

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Longeveron at a glance

Latest quarterQ2 2026

Revenue$287K

Revenue Y/Y-9%

Operating marginn/m

IndustryPharmaceutical Preparations

Longeveron, Q2 2026: revenue $287K (-9% year over year). The chart follows the revenue to costs, profit and cash.

Longeveron: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Biovie Nov 6, 2026
Acrivon Therapeutics Nov 6, 2026
Entera Bio Nov 6, 2026
Precision Biosciences Nov 5, 2026
Sintx Technologies Nov 5, 2026
Microbot Medical Nov 5, 2026
Bioxytran Nov 5, 2026
Palvella Therapeutics Nov 5, 2026
ANI Pharmaceuticals Nov 5, 2026
Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.